Lyra Therapeutics Inc LYRA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 02/03/23 EST
2.75quote price arrow down-0.01 (-0.36%)
Volume
34,856
52 week range
2.35 - 8.18
Loading...
  • Open2.78
  • Day High3.00
  • Day Low2.73
  • Prev Close2.76
  • 52 Week High8.18
  • 52 Week High Date04/18/22
  • 52 Week Low2.35
  • 52 Week Low Date12/20/22

Key Stats

  • Market Cap87.524M
  • Shares Out31.83M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-0.45
  • YTD % Change-12.42

KEY STATS

  • Open2.78
  • Day High3.00
  • Day Low2.73
  • Prev Close2.76
  • 52 Week High8.18
  • 52 Week High Date04/18/22
  • 52 Week Low2.35
  • 52 Week Low Date12/20/22
  • Market Cap87.524M
  • Shares Out31.83M
  • 10 Day Average Volume0.04M
  • Dividend-
  • Dividend Yield-
  • Beta-0.45
  • YTD % Change-12.42

RATIOS/PROFITABILITY

  • EPS (TTM)-2.79
  • P/E (TTM)-0.99
  • Fwd P/E (NTM)-1.59
  • EBITDA (TTM)-53.644M
  • ROE (TTM)-77.86%
  • Revenue (TTM)1.623M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-3,367.84%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/07/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lyra Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy. The Company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected...
Harlan Waksal M.D.
Executive Chairman of the Board
Maria Palasis Ph.D.
President, Chief Executive Officer, Director
Jason Cavalier
Chief Financial Officer, Treasurer, Secretary
Address
480 Arsenal Way
Watertown, MA
02472
United States

Top Peers

SYMBOLLASTCHG%CHG
IMPL
Impel Pharmaceuticals Inc
3.25-0.14-4.13%
LVTX
LAVA Therapeutics NV
3.74+0.11+3.03%
FIXX
Homology Medicines Inc
1.69+0.03+1.81%
HCWB
HCW Biologics Inc
1.95-0.05-2.50%
SPRO
Spero Therapeutics Inc
1.90+0.07+3.83%